CONCORDBIO · Concord Biotech Limited · Financials
Volume · Nov 13
18.04K
Avg daily vol (8 sessions)
25.44K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
10.55B
-12.1%
FY2026
Net Income
2.61B
-29.8%
FY2026
Operating Cash Flow
2.67B
+9.1%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 |
|---|---|---|---|---|
| INR | 11.7B | 10.55B | 12B | 10.17B |
| INR | 747.67M | 744.59M | 543.74M | 535.92M |
| INR | 2.35M | 2.83M | 5.29M | 25.52M |
| INR | 946.78M | 854.18M | 1.23B | 1.04B |
| INR | 2.82B | 2.61B | 3.72B | 3.08B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2026: 2.75B in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.